Orlistat in the prevention of diabetes in the obese patient

References

• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288298197 Erratum in: JAMA, 2003 289:178. JAMA, 2004 291:219612479763
   PubMed Web of Science ®Google Scholar
• [ADA] American Diabetes AssociationEconomic costs of diabetes in the U.S. in 2002Diabetes Care2003269173212610059
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Clinical Practice RecommendationsPrevention or delay of type 2 diabetesDiabetes Care200427Suppl 1S475414693925
   PubMedGoogle Scholar
• AndersonDCJrPharmaological prevention or delay of type 2 diabetes mellitusAnn Pharmacother200539102915562143
   PubMed Web of Science ®Google Scholar
• AndrulionyteLZacharovaJChiassonJLSTOP-NIDDM Study GroupCommon polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trialDiabetologia20044721768415592662
   PubMed Web of Science ®Google Scholar
• [APCSC] Asia Pacific Cohort Studies CollaborationThe burden of overweight and obesity in the Asia-Pacific regionObes Rev20078191617444961
   PubMed Web of Science ®Google Scholar
• BaysHAdiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of EverythingExpert Rev Cardiovasc Ther2005339340415889967
   PubMedGoogle Scholar
• BaysHBlondLRosensonRAdiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?Expert Rev Cardiovasc Ther200648719517173503
   PubMedGoogle Scholar
• BenjaminSMValdezRGeissLSEstimated number of adults with prediabetes in the U.S. in 2000Diabetes Care200326645912610015
   PubMed Web of Science ®Google Scholar
• BorstSEThe role of TNF-alpha in insulin resistanceEndocrine2004231778215146098
   PubMed Web of Science ®Google Scholar
• BoykoEJFujimotoWYLeonettiDLVisceral adiposity and risk of type 2 diabetes: a prospective study among Japanese AmericansDiabetes Care2000234657110857936
   PubMed Web of Science ®Google Scholar
• BrandbergJLönnLPeltonenMBody composition changes during 4 years of treatment with orlistat vs placebo (The XENDOS study)Int J Obes200327Suppl 1S100
   Google Scholar
• BuchananTAXiangAHPetersRKPreservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic womenDiabetes200251279680312196473
   PubMed Web of Science ®Google Scholar
• Calles-EscandonJCipollaMDiabetes and endothelial dysfunction: a clinical perspectiveEndocr Rev200122365211159815
   PubMed Web of Science ®Google Scholar
• CarriereFRenouCRansacSInhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteersAm J Physiol Gastrointest Liver Physiol2001281G162811408251
   PubMed Web of Science ®Google Scholar
• ChanJMRimmEBColditzGAObesity, fat distribution, and weight gain as risk factors for clinical diabetes in menDiabetes Care19941796197988316
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGGomisRAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP NIDDM trialJAMA20032904869412876091
   PubMed Web of Science ®Google Scholar
• ColditzGAWilletWCRotznitzkyAWeight gain as a risk factor for clinical diabetes in womenAnn Intern Med199512248167872581
   PubMed Web of Science ®Google Scholar
• ConigraveKMHuBFCamargoCAA prospective study of drinking pattern in relation to risk of type 2 diabetes among menDiabetes2001502390511574424
   PubMed Web of Science ®Google Scholar
• CorpeleijnESarisWHJansenEHPostprandial interleukin-6 release from skeletal muscle in men with impaired glucose tolerance can be reduced by weight lossJ Clin Endocrinol Metab20059058192416030153
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023591004101011937179
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• DamciTYalinSBalciHOrlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patientsDiabetes Care20042710778015111524
   PubMed Web of Science ®Google Scholar
• DandonaPAljadaABandyopadhyayAInflammation: the link between insulin resistance, obesity and diabetesTrends Immunol2004254714698276
   PubMed Web of Science ®Google Scholar
• DavidsonMHHauptmanJDi GirolamoMWeight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trialJAMA1999281235429918478
   PubMed Web of Science ®Google Scholar
• DidangelosTPThanopoulouAKBousboulasSHThe ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) StudyCurr Med Res Opin200420139340115383188
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJDREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet2006368109610516997664
   PubMed Web of Science ®Google Scholar
• EddyDMSchlessingerLKahnRClinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetesAnn Intern Med20051432516416103469
   PubMed Web of Science ®Google Scholar
• EdelsteinSLKnowlerWCBainRPPredictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studiesDiabetes199746701109075814
   PubMed Web of Science ®Google Scholar
• EldorRRazILipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetesDiabetes Res Clin Pract2006742 SupplS38
   Google Scholar
• ErikssonKFLindgardeFPrevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility studyDiabetologia19913489181778354
   PubMed Web of Science ®Google Scholar
• [ECDCDM] The Expert Committee on the Diagnosis and Classification of Diabetes MellitusReport of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes199720118397
   Web of Science ®Google Scholar
• FerranniniEBarrettEJBevilacquaSEffect of fatty acids on glucose production and utilization in manJ Clin Invest1983721737476138367
   PubMed Web of Science ®Google Scholar
• FerreiraSRLerarioDDGimenoSGObesity and central adiposity in Japanese immigrants: role of the Western dietary patternJ Epidemiol200212431812462278
   PubMedGoogle Scholar
• FoxcroftDROrlistat for the treatment of obesity: cost utility modelObes Rev20056323816246217
   PubMed Web of Science ®Google Scholar
• FreemanDJNorrieJSattarNPravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention StudyCirculation20011033576211157685
   PubMed Web of Science ®Google Scholar
• FungTTHuFBPereiraMAWhole-grain intake and the risk of type 2 diabetes: a prospective study in menAm J Clin Nutr2002765354012197996
   PubMed Web of Science ®Google Scholar
• FungTTSchulzeMMansonJEDietary patterns, meat intake, and the risk of type 2 diabetes in womenArch Intern Med200416422354015534160
   PubMed Web of Science ®Google Scholar
• GruberANasserKSmithRDiabetes prevention: is there more than lifestyle changes?Int J Clin Pract200660590416700860
   PubMed Web of Science ®Google Scholar
• GuercioliniRMode of action of orlistatInt J Obes Relat Metab Disord199721S12239225172
   PubMed Web of Science ®Google Scholar
• HalpernAManciniMCSuplicyHLatin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patientsDiabetes Obes Metab20035180812681025
   PubMed Web of Science ®Google Scholar
• HalpernAManciniMCDiabesity: are weight loss medications effective?Treat Endocrinol20054657415783244
   PubMedGoogle Scholar
• HanssonLLindholmLHNiskanenLEffect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialLancet1999353611610030325
   PubMed Web of Science ®Google Scholar
• [HOPE] Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyLancet2000355253910675071
   PubMed Web of Science ®Google Scholar
• HeymsfieldSBSegalKRHauptmanJEffects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adultsArch Intern Med20001601321610809036
   PubMed Web of Science ®Google Scholar
• HoffmannJSpenglerMEfficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen StudyDiabetes Care19941756168082525
   PubMed Web of Science ®Google Scholar
• HoffmannJSpenglerMEfficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II StudyAm J Med1997103483909428831
   PubMed Web of Science ®Google Scholar
• HollanderPAElbeinSCHirschIBRole of orlistat in the treatment of obese patients with type 2 diabetesDiabetes Care199821128812949702435
   PubMed Web of Science ®Google Scholar
• HsiehCJWangPWLiuRTOrlistat for obesity: benefits beyond weight lossDiabetes Res Clin Pract200567788315620437
   PubMed Web of Science ®Google Scholar
• HuFBSigalRJRich-EdwardsJWWalking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective studyJAMA19992821433910535433
   PubMed Web of Science ®Google Scholar
• HuFBMansonJEStampferMJDiet, lifestyle, and the risk of type 2 diabetes mellitus in womenN Engl J Med2001345790711556298
   PubMed Web of Science ®Google Scholar
• [IDF] International Diabetes FederationDiabetes prevalence2006 [online] Accessed 12 October 2006. URL:http://www.idf.org/home/index.cfm?node=264
   Google Scholar
• IsomaaBAlmgrenPTuomiTCardiovascular morbidity and mortality associated with the metabolic syndromeDiabetes Care2001246839911315831
   PubMed Web of Science ®Google Scholar
• JamesWPTRigbyNLeachRThe obesity epidemic, metabolic syndrome and future prevention strategiesEur J Cardiovasc Prev Rehabil2004113815167200
   PubMed Web of Science ®Google Scholar
• JamesWPTThe SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patientsEur Heart J20057SupplL448
   Google Scholar
• JuliusSKjeldsenSEWeberMVALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KanayaAMHerrigtonDVittinghoffEfor the Heart and Estrogen/Progestin Replacement Study (HERS)Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trialAnn Intern Med20031381912513038
   PubMed Web of Science ®Google Scholar
• KeatingGMJarvisBOrlistat: in the prevention and treatment of type 2 diabetes mellitusDrugs200161210719 discussion 2120–111735640
   PubMed Web of Science ®Google Scholar
• KelleyDEWilliamsKPriceJPlasma fatty acids, adiposity and variance of skeletal muscle insulin resistance in type 2 diabetes mellitusJ Clin Endocrinol Metab20018654121911701715
   PubMed Web of Science ®Google Scholar
• KelleyDEBrayGAPi-SunyerFXClinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trialDiabetes Care200225103341 Erratum in: Diabetes Care, 26:97112032111
   PubMed Web of Science ®Google Scholar
• KelleyDEKullerLHMcKolanisTMEffects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetesDiabetes Care200427334014693963
   PubMed Web of Science ®Google Scholar
• KissebahAHKrakowerGRRegional adiposity and morbidityPhysiol Rev1994747618117938225
   PubMed Web of Science ®Google Scholar
• KnowlerWCPettittDJSaadMFDiabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesisDiab Metab Rev19906127
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• KosakaKNodaMKuzuyaTPrevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT malesDiabetes Res Clin Pract2005671526215649575
   PubMed Web of Science ®Google Scholar
• KriskaAMPereiraMAHansonRLAssociation of physical activity and serum insulin concentrations in two populations at high risk for type 2 diabetes but differing by BMIDiabetes Care20012411758011423498
   PubMed Web of Science ®Google Scholar
• LaceyLAWolfAO’sheaDCost-effectiveness of orlistat for the treatment of overweight and obese patients in IrelandInt J Obes (Lond)2005299758215852050
   PubMed Web of Science ®Google Scholar
• LindgrenPLindstromJTuomilehtoJDPS Study GroupLifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effectiveInt J Technol Assess Health Care2007231778317493303
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032115637412872052
   PubMed Web of Science ®Google Scholar
• Lopez-RidauraRWilletCWRimmBEMagnesium intake and risk of type 2 diabetes in men and womenDiabetes Care200427134914693979
   PubMed Web of Science ®Google Scholar
• LovejoyJCDietary fatty acids and insulin resistanceCurr Atheroscler Rep199912152011122713
   PubMedGoogle Scholar
• MaetzelARuofJCovingtonMEconomic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitusPharmacoeconomics2003215011212696990
   PubMed Web of Science ®Google Scholar
• ManciaGBrownMCastaigneAINSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)Hypertension200341431612623939
   PubMed Web of Science ®Google Scholar
• MarshallJAHammanRFBaxterJHigh-fat, low-carbohydrate diet and the etiology of non-insulin-dependent diabetes mellitus: The San Luis Valley Diabetes StudyAm J Epidemiol19911345906031951264
   PubMed Web of Science ®Google Scholar
• MatherHMKeenHThe Douthall Diabetes survey: prevalence of known diabetes in Asians and EuropeansBr Med J1985291108143931804
   PubMed Web of Science ®Google Scholar
• MeierJJGallwitzBNauckMAGlucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitusBioDrugs2003179310212641488
   PubMed Web of Science ®Google Scholar
• MeyerKAKushiLHJacobsDRJrCarbohydrates, dietary fiber, and incident type 2 diabetes in older womenAm J Clin Nutr2000719213010731498
   PubMed Web of Science ®Google Scholar
• MilesJMLeiterLHollanderPEffect of orlistat in overweight and obese patients with type 2 diabetes treated with metforminDiabetes Care200225711238 Erratum in: Diabetes Care, 25 (9):167112087008
   PubMed Web of Science ®Google Scholar
• MokdadAHFordESBowmanBADiabetes trends in the U.S.: 1990–1998Diabetes Care20002312788310977060
   PubMed Web of Science ®Google Scholar
• MonteiroCABenicioMHACondeWLShifting obesity trends in BrazilEur J Clin Nutr2000433416
   Google Scholar
• NarayanKMWBoyleJPThompsonTJLifetime risk for diabetes mellitus in the United StatesJAMA200329018849014532317
   PubMed Web of Science ®Google Scholar
• NauckMAMeierJJGlucagon-like peptide 1 and its derivatives in the treatment of diabetesRegul Pept20051281354815780433
   PubMed Web of Science ®Google Scholar
• NorrisSLChowdhuryFMVan LeKEffectiveness of community health workers in the care of persons with diabetesDiabet Med2006235445616681564
   PubMed Web of Science ®Google Scholar
• PadwalRLaupacisAAntihypertensive therapy and incidence of type 2 diabetes: a systematic reviewDiabetes Care2004272475514693997
   PubMed Web of Science ®Google Scholar
• PadwalRMajumdarSRJohnsonJAA systematic review of drug therapy to delay or prevent type 2 diabetesDiabetes Care2005287364415735219
   PubMed Web of Science ®Google Scholar
• PanXRLiGWHuYHEffects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes StudyDiabetes Care199720537449096977
   PubMed Web of Science ®Google Scholar
• ParkKSPrevention of type 2 diabetes mellitus from the viewpoint of geneticsDiabetes Res Clin Pract200466Suppl 1S33515563977
   PubMed Web of Science ®Google Scholar
• ParkKSShinHDParkBLPutative association of peroxisome proliferator-activated receptor gamma co-activator 1beta (PPARGC1B) polymorphism with type 2 diabetes mellitusDiabet Med2006a236354216759305
   PubMed Web of Science ®Google Scholar
• ParkKSShinHDParkBLPolymorphisms in the leptin receptor (LEPR) – putative association with obesity and T2DMJ Hum Genet200651859116333525
   PubMed Web of Science ®Google Scholar
• PepineCJHandbergEMCooper-DeHoffRMINVEST InvestigatorsA calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialJAMA200329028051614657064
   PubMed Web of Science ®Google Scholar
• PerryIJWannametheeSGWalkerMKProspective study of risk factors for development of non-insulin dependent diabetes in middle aged British menBr Med J199531056047888929
   PubMed Web of Science ®Google Scholar
• PiattiPMMontiLDDavisSNEffects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM subjectsDiabetologia19961996103128720610
   PubMedGoogle Scholar
• PontiroliAEFolliFPaganelliMLaparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled studyDiabetes Care2005282703916249543
   PubMed Web of Science ®Google Scholar
• PrisantLMPreventing type II diabetes mellitusJ Clin Pharmacol2004444061315051749
   PubMed Web of Science ®Google Scholar
• RandlePJGarlandPBHalesCNThe glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitusLancet196313785913990765
   PubMedGoogle Scholar
• RandlePJRegulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 yearsDiabetes Metab Rev1998142638310095997
   PubMed Web of Science ®Google Scholar
• ReavenGMThe role of insulin resistance in human diseaseDiabetes198837159516073056758
   PubMed Web of Science ®Google Scholar
• RetnakaranRHanleyAJZinmanBDoes hypoadiponectinemia explain the increased risk of diabetes and cardiovascular disease in South asians?Diabetes Care2006291950416873811
   PubMed Web of Science ®Google Scholar
• RichelsenBTonstadSRössnerSEffect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled studyDiabetes Care200730273217192328
   PubMed Web of Science ®Google Scholar
• RossnerSSjöströmLNoackREuropean Orlistat Obesity Study GroupWeight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesityObes Res20008496110678259
   PubMedGoogle Scholar
• SamuelssonLGottsaterALindgardeFDecreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factorsDiabetes Obes Metab2003519520112681027
   PubMed Web of Science ®Google Scholar
• SantomauroATBodenGSilvaMEOvernight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjectsDiabetes19994818364110480616
   PubMed Web of Science ®Google Scholar
• SatterfieldDWVolanskyMCaspersenCJCommunity-based lifestyle interventions to prevent type 2 diabetesDiabetes Care20032626435212941733
   PubMed Web of Science ®Google Scholar
• SaydahSHLoriaCMEberhardtMSSubclinical states of glucose intolerance and risk of death in the U.SDiabetes Care2001254475311289466
   PubMedGoogle Scholar
• ScheenAJErnestPNew antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistatDiabetes Metab2002284374512522323
   PubMed Web of Science ®Google Scholar
• ScheenAJIs there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?Drugs2003639335112699398
   PubMed Web of Science ®Google Scholar
• SchulzLOBennettPHRavussinEEffects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the USDiabetes Care20062918667116873794
   PubMed Web of Science ®Google Scholar
• SjöströmLRissanenAAndersenTEuropean Multicentre Orlistat Study GroupRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patientsLancet1998352167729683204
   PubMed Web of Science ®Google Scholar
• SjöströmLLindroosAKPeltonenMLifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgeryN Engl J Med200435126839315616203
   PubMed Web of Science ®Google Scholar
• SwinburnBAMetcalfPALeySJLong-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intoleranceDiabetes Care2001246192411315819
   PubMed Web of Science ®Google Scholar
• TanKTsoATamSAcute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitusDiabet Med200219944812421432
   PubMed Web of Science ®Google Scholar
• TenenbaumAMotroMFismanEZPeroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery diseaseCirculation2004109219720215123532
   PubMed Web of Science ®Google Scholar
• ThomsenCStormHHolstJJDifferential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetesAm J Clin Nutr2003776051112600850
   PubMed Web of Science ®Google Scholar
• TongPCLeeZSSeaMMThe effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetesArch Intern Med200216224283512437401
   PubMed Web of Science ®Google Scholar
• TorgersonJSHauptmanJBoldrinMNXENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patientsDiabetes Care20042715561 Erratum in: Diabetes Care, 2004 27:85614693982
   PubMed Web of Science ®Google Scholar
• TsaiAGWaddenTASystematic review: an evaluation of major commercial weight loss programs in the United StatesAnn Intern Med2005142566615630109
   PubMed Web of Science ®Google Scholar
• TuomilehtoJLindstronJErikssonJGPrevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranceN Engl J Med200134413435011333990
   PubMed Web of Science ®Google Scholar
• TuomilehtoJPrimary prevention of type 2 diabetes: lifestyle intervention works and saves money, but what should be done with smokers?Ann Intern Med2005142381315738457
   PubMed Web of Science ®Google Scholar
• [UKPDS] United Kingdom Prospective Diabetes Study GroupUK prospective diabetes study 16: overview of 6 years’ therapy of type II diabetesDiabetes1995441249587589820
   PubMed Web of Science ®Google Scholar
• UwinNShawJZimmetPImpaired glucose tolerance and impaired fasting glycaemia: the current status on definition and interventionDiab Med20021970823
   PubMed Web of Science ®Google Scholar
• ValsamakisGMcTernanPGChettyRModest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokinesMetabolism200453430415045687
   PubMed Web of Science ®Google Scholar
• Van DamRMRimmEBWillettWCDietary patterns and risk of type 2 diabetes mellitus in US menAnn Intern Med2002136201911827496
   PubMed Web of Science ®Google Scholar
• Van DamRMHuFBCoffee consumption and risk of type 2 diabetes: a systematic reviewJAMA20052949710415998896
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTSonneJIncretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitusJ Clin Endocrinol Metab20038827061312788877
   PubMed Web of Science ®Google Scholar
• WangYMiJShanXYIs China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in ChinaInt J Obes (Lond)2007311778816652128
   PubMed Web of Science ®Google Scholar
• WeyerCBogardusCMottDMThe natural hystory of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJ Clin Investig19991047879410491414
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenAGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042710475315111519
   PubMed Web of Science ®Google Scholar
• WilliamsKVMullenMLKelleyDEThe effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetesDiabetes Care199821289538962
   PubMed Web of Science ®Google Scholar
• WingRRKoeskeREpsteinLHLong-term effects of modest weight loss in type II diabetic patientsArch Intern Med19871471749533310940
   PubMed Web of Science ®Google Scholar
• WingRRShoemakerMMarcusMDVariables associated with weight loss and improvements in glycemic control in type II diabetic patients in behavioral weight control programsInt J Obes1990144955032401586
   PubMed Web of Science ®Google Scholar
• [WHO] World Health OrganizationObesity: preventing and managing the global epidemicReport of WHO consultation on obesity2000GenevaWorld Health Organization
   Google Scholar
• WuSIChouPTsaiSTThe impact of years since menopause on the development of impaired glucose toleranceJ Clin Epidemiol2001541172011166525
   PubMed Web of Science ®Google Scholar
• XuGStoffersDAHabenerJFExendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic ratsDiabetes1999482270610580413
   PubMed Web of Science ®Google Scholar
• YusufSOstergrenJBGersteinHCCandesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program InvestigatorsEffects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failureCirculation20051124853 Erratum in: Circulation, 112:e29215983242
   PubMed Web of Science ®Google Scholar
• ZacharovaJChiassonJLLaaksoMSTOP-NIDDM Study GroupThe common polymorphisms (single nucleotide polymorphism [SNP]+45 and SNP+276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trialDiabetes2005a54893915734870
   PubMed Web of Science ®Google Scholar
• ZacharovaJTodorovaBRChiassonJLSTOP-NIDDM Study GroupThe G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trialJ Intern Med2005b2571859315656877
   PubMed Web of Science ®Google Scholar
• ZhangYHowardBVCowanLDThe effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women: the Strong Heart studyDiabetes Care200225500411874937
   PubMed Web of Science ®Google Scholar
• ZhiJMeliaATEggersHReview of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteersJ Clin Pharmacol199535110388626884
   PubMed Web of Science ®Google Scholar